Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

RenovoRx's innovative RenovoCath and TAMP platform show promising clinical data. Click here to read why RNXT stock presents ...

The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat movement-related symptoms of Parkinson's disease, the drugmaker said on Tuesday.

A couple of months ago, healthcare equity research analyst Jared Holz from Mizuho spoke about Viking potentially being an acquisition target. During his discussion, Holz suggested that Viking could ...

The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.

Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) stock is up 6% at $465.02 at last glance, after the U.S. Food and Drug ...

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...